Skip to Content
Merck
  • Selective inhibition of the NLRP3 inflammasome by targeting to promyelocytic leukemia protein in mouse and human.

Selective inhibition of the NLRP3 inflammasome by targeting to promyelocytic leukemia protein in mouse and human.

Blood (2013-02-23)
Yu-Hsun Lo, Yu-Wen Huang, Yung-Hsuan Wu, Chi-Shan Tsai, Yu-Chuan Lin, Shu-Ting Mo, Wen-Chih Kuo, Ya-Ting Chuang, Si-Tse Jiang, Hsiu-Ming Shih, Ming-Zong Lai
ABSTRACT

The functional activities of the tumor suppressor promyelocytic leukemia protein (PML) are mostly associated with its nuclear location. In the present study, we discovered an unexpected role of PML in NLRP3 inflammasome activation. In PML-deficient macrophages, the production of IL-1β was strongly impaired. The expression of pro-IL-1β, NLRP3, ASC, and procaspase-1 was not affected in Pml(-/-) macrophages. PML deficiency selectively reduced the processing of procaspase-1. We further showed that PML is required for the assembly of the NLRP3 inflammasome in reconstitution experiment. All PML isoforms were capable of stimulating NLRP3 inflammasome activation. In Pml(-/-) macrophages, the generation of reactive oxygen species and release of mitochondrial DNA were decreased. The involvement of PML in inflammasome activation constitutes an important activity of PML and reveals a new mechanism underlying the inflammasome activation. In addition, downregulation of PML by arsenic trioxide suppressed monosodium urate (MSU)-induced IL-1β production, suggesting that targeting to PML could be used to treat NLRP3 inflammasome-associated diseases.

MATERIALS
Product Number
Brand
Product Description

Supelco
Arsenic(III) oxide, reference material for titrimetry, certified by BAM, >99.5%
Sigma-Aldrich
Arsenic(III) oxide, 99.995% trace metals basis
Sigma-Aldrich
Arsenic(III) oxide, ReagentPlus®, ≥99.0%
Sigma-Aldrich
Arsenic(III) oxide, ACS reagent (primary standard)